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Abstract 
The aim of this study was to analyze patterns of metastatic spread from cutaneous head and 
neck melanoma which are said to be highly variable. The medical records of 145 patients with 
pathologically proven metastatic melanoma were reviewed retrospectively. The location of 
pathologically positive lymph nodes was compared with clinically predicted spread, and 
patients with metastatic disease in areas outside of predicted drainage patterns were 
considered aberrant. There were 33 curative and 73 elective neck dissections. Twenty-one of 
77 patients undergoing parotidectomy had positive results for metastases. Clinical prediction 
proved to be correct in 33 of 45 cases (73.3%). Two patients with lateralized melanomas were 
initially seen with contralateral metastases. Six of 45 patients (13.3%) developed contralateral 
metastases after neck dissection. Patients with clinical involvement of the parotid gland were 
at high risk of occult neck disease (40%). Patients undergoing neck dissection for primaries 
originating in face, forehead, coronal scalp, periauricular area, and upper neck should be 
considered for parotidectomy. Patients with posterior scalp and posterior neck primaries 
should be considered for selective neck dissection in conjunction with posterior 
lymphadenectomy. In patients with coronal scalp and periauricular primaries, a complete neck 
dissection including parotidectomy is recommended approach. 
 
Keywords: head and neck melanoma, neck dissection, clinical prediction, lymphatic drainage 
pattern, nodal status 
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INTRODUCTION 
Treatment of melanoma of the head and neck is a complex issue. The behaviour of this 
malignancy is aggressive, and it has an overall worse prognosis than that of other skin sites19.  
 
Histological involvement of regional lymph nodes by metastases of malignant melanoma in 
the head and neck region is a very poor prognostic sign, and it appears to carry an even more 
ominous prognosis than histological involvement of axillary or inguinal lymph nodes in 
draining melanomas of the trunk or extremities32. Therefore, accurate localization of 
pathologically involved cervical lymph nodes is crucial in the treatment of these patients.  
 
Some studies have reported that patterns of lymphatic drainage from a given area of skin in 
patients with melanoma are highly variable from patient to patient and that accurate clinical 
prediction of lymphatic pathways is not possible39, 41. This study is design to determine the 
accuracy of clinically predicting the distribution of pathologically involved lymph nodes 
related to primary melanoma site. 
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MATERIALS AND METHODS 
The medical records of patients with primary cutaneous head and neck melanomas, who were 
referred to the Department of Maxillofacial Surgery of the University Hospital Dubrava, 
University of Zagreb School of Medicine, from January 1, 1985 to December 31, 2005, were 
reviewed retrospectively. Patients with primary melanomas of the head and neck who 
underwent primary surgical treatment were included. The exclusion criteria were as follows: 
patients who did not undergo primary surgical treatment; patients with primary cutaneous 
melanoma localized outside of the head and neck region; patients who had been previously 
excised, had local recurrence, or neck metastasis and patients with external ear melanomas. 
Among 145 patients with cutaneous head and neck melanomas, 39 patients underwent wide 
local excision due to their thickness (<1mm), while 106 patients underwent neck dissection.  
 
All cases were re-classified according to the AJCC melanoma staging system1. Primary tumor 
mitotic rate has been excluded from our survival analysis as potential predictive factor 
because it was not a factor earlier classifications and data on this are incomplete and 
unreliable. The harvested lymph nodes were evaluated using serial sectioning with 
hematoxylin-eosin (H&E) staining while immunohistochemical staining with antibodies for 
S-100p, HMB-45 and MART-1 were used for patients when H&E did not reveal evidence of 
metastatic disease since this procedure has 10-30% higher sensitivity for identifying 
micrometastases compared with conventional H&E staining9, 17, 24, 42. The location of 
pathologically positive lymph nodes was compared with clinically predicted spread, and all 
patients with metastatic disease in areas outside of predicted drainage patterns (including 
drainage to contralateral lymph node of neck) were considered aberrant. Follow-up intervals 
were calculated in months from the date of first treatment at our Department to the date of last 
follow-up or death. 
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Statistical methods 
In this retrospective, single-institution study, the clinical features, including age, gender, 
histological type, and localization of the tumours were obtained from clinical records. Patient 
characteristics were recorded on MS Excel® spreadsheets and analyzed using MedCalc 
statistical software (Version 11.3.1 © 1993-2010. MedCalc Software bvba, Broekstraat 52, 
9030 Mariakerke, Belgium). Fisher’s exact test was used to determine the level of 
significance for categorical variables. The Kaplan-Meier statistical method was used to 
generate survival curves. Differences in survival were analysed using a log-rank test. Values 
of P<0.05 were considered statistically significant. 
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RESULTS 
Over the 21-year period, 145 patients with head and neck cutaneous melanomas were 
surgically treated at the Department of Maxillofacial Surgery, University Hospital Dubrava, 
in Zagreb, Croatia. There were altogether 106 neck dissections, among which 33 were 
curative and 73 were elective procedures. Radical neck dissections were performed as well as 
elective and curative treatments (14 vs. 12), while the selective were used almost exclusively 
as an elective (40 vs. 1). More than two thirds of elective selective neck dissections were 
supraomohyoid neck dissection (34/40), and the only curative selective dissection was 
performed for regions 2-5. Modified radical neck dissections were performed more often as 
elective procedures (12 vs. 7), while extended radical neck dissections were used more often 
as curative treatments (10 vs. 6). There were 4 bilateral neck dissections (one bilateral 
modified radical neck dissections, two modified radical neck dissections with contralateral 
radical neck dissection, and one radical neck dissection with contralateral selective neck 
dissection). Type of performed neck dissections are summarized in Table 1. 
 
Figure 1 shows Kaplan-Meier survival curves of patients with an ulcerated melanoma 
compared with patients with a nonulcerated melanoma. Comparation of survival curves has 
shown significant difference with respect to survival (P=0.048). Age was considered a 
discontinuous variable and was divided into three arbitrary groups: twenty-nine patients were 
aged 21 to 40, 33 patients were aged 41 to 60, and 44 patients were above 61 years old. The 
age groups failed to show any significant difference with respect to survival [(P= 0.624), 
Figure 2]. Gender was analyzed by log-rank test comparison of survival curves. Cumulative 
survival at 5 years for entire group was 61.3%. The gender groups differed significantly with 
respect to survival [(P= 0.042), Figure 3]. Lymph node involvement significantly decreased 
survival rates (P<0.01). Figure 4 shows comparative melanoma-specific survival among 
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patients compared to nodal status. Analysis of influence on survival of negative neck 
compared with nodal disease in the parotid gland and neck and with nodal disease in the 
parotid lymphatics or neck alone has shown significant difference in survival rates (P<0.01). 
When all node-positive (n=45) and node-negative (n=51) patients were considered as two 
different groups, the cumulative survival was 44% and 87% at 5 years, respectively (P< 0.01).  
 
Extracapsular extension (ECE) of melanomas was identified in 9 of 45 (20%) patients with 
histological positive nodes. There was no significant difference in survival between patients 
with ECE compared with patients without ECE (P=0.956). Lymph node metastases were 
found in 84.8% (28 of 33) of curative neck dissections, and occult metastases were identified 
in 17.8% (13 of 73) of elective neck dissections. In 77 patients, a parotidectomy was carried 
out in conjunction with a neck dissection. Among the elective procedures, there were 34 
superficial and 28 total parotidectomies. The therapeutic procedures comprised 9 superficial 
and 6 total parotidectomies. Twenty-one patients undergoing parotidectomy as a part of 
regional lymphadenectomy had involvement of the parotid lymphatics (11 of 15 in therapeutic 
parotidectomy and 10 of 62 in elective procedures). Among 15 patients with clinical 
metastatic melanoma of the parotid, 9 patients (60%) had pathological involvement of 
cervical lymph nodes (6 elective and 3 curative neck dissections). Mean follow up was 56.3 
months (range, 0-243). There was one postoperative death involving a 72-year-old man who 
suffered myocardial infarction and died 6 days after surgical therapy. As adjuvant treatment, 
the majority of patients received interferon (n=23), followed by chemotherapy (n=18), 
chemotherapy with radiation (n=3), radiation alone (n=1), and radiation with immunotherapy 
(n=1) and they were all included in the study group. 
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After eliminating patients with histological negative necks (n= 51), patients with nodal 
metastases from an unknown primary melanoma site (n= 6) and patients with primaries 
outside the head and neck region with regional metastases (n= 4), 45 patients were eligible for 
this study. Clinical characteristics of these patients are summarized in Table 2. The study 
group included 28 men and 17 women with a median age of 49 years (range, 21-75 years).  
 
The mean tumour thickness in the study group was 4.2 mm (range, 1-10 mm). Based on 
thickness, melanomas were stratified into thin (n=0), intermediate (n=17) and thick (n=28). 
The number of nodal metastases per patient averaged 3.98 (range, 1-17). 
 
The skin of the head and neck was divided into 6 anatomic subsites (Figure 5). Pathological 
findings were correlated with primary melanoma site, which was assigned to the one of six 
anatomic subsites and then compared with clinical prediction. The algorithm for determining 
drainage was based according to the patterns described by O’ Brien et al.30. The correlation 
between clinical prediction based on primary melanoma site and anatomic distribution of 
nodal metastases is shown in Table 3. 
 
Primary melanomas of the forehead and face were metastasing to the parotid gland or neck 
levels 1-3 in 12 of 16 cases. One patient with a cheek melanoma developed regional 
metastases outside of the predicted area (contralateral level 3 lymph nodes) and one patient 
with upper lip melanoma had regional metastases at level 1 and 4 lymph nodes. A patient with 
forehead melanoma had positive nodes at level 1 and 5 in the ipsilateral neck. One patient 
with a melanoma of the face had pathological involvement of an ipsilateral parotid gland and 
level 2-5 lymph nodes. Primary melanomas of the periauricular area and coronal scalp spread 
to the parotid region or neck level 1-5 in 15 of 16 cases. One patient with a coronal scalp 
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malignancy developed ipsilateral pathological involvement of level 1 lymph nodes and 
contralateral metastatic disease at level 2 lymph nodes. Melanomas of the posterior scalp and 
posterior neck were metastasing to the occipital lymph nodes or level 2-5 lymph nodes in 2 of 
6 patients. Two patients with melanomas of the posterior scalp developed postauricular lymph 
node involvement. One of these two patients had also metastatic spread to neck levels 2-5, 
while one patient with the same primary site developed metastatic disease in nuchal lymph 
nodes. Nuchal lymph node involvement occurred also in patients with a primary melanoma of 
posteroinferior neck. Melanomas of the superior neck were predicted to spread to level 1-5 
lymph nodes, which were found to be true in 3 of 6 cases. Three patients developed 
metastases in parotid nodes, which were considered an unpredicted lymphatic drainage 
pattern. One patient with melanoma of the jugular area (anteroinferior neck) developed 
regional disease in the predicted domain (level 6 lymph node). Two patients with lateralized 
melanomas were initially seen with contralateral metastatic disease. Six of 45 patients 
(13.3%) developed drainage to contralateral levels after ipsilateral neck dissection. Level 1 
was more commonly involved with anterior primary sites (face, forehead, coronal scalp, 
periauricular region and upper neck) than posterior sites (posterior scalp and neck), 35.9% vs. 
0% respectively. Involvement of level 4 occurred in 15.6% (7 of 45), ranging from 0% for 
upper neck melanomas to 33.3% for melanomas of posterior scalp and neck. Regional 
metastatic disease at level 5 occurred in 22.2% (10 of 45), with lowest incidence for upper 
neck melanomas (0%) and highest for coronal neck and periauricular melanomas (37.5%).  
 
Postauricular and nuchal involvement occurred only in cases of posterior scalp and posterior 
neck melanomas. Clinical prediction proved to be correct in 73.3% of cases. Twelve patients 
(26.7%) showed lymphatic drainage inconsistent with clinical prediction. Thick melanomas 
proved to be associated with unpredicted drainage patterns 75% of the time (9 out of 12), 
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while intermediate melanomas showed aberrant metastatic spread 25% of the time (3 out of 
12). 
 
In the follow up period, 29 of the 45 node-positive patients developed recurrence at the mean 
interval of 15.8 months (from 2 to 86 months). Among 51 node-negative patients 10 
developed recurrence at a mean interval of 33.8 months (from 6 to 86 months). From a total 
of 29 recurrences, the first clinical signs of recurrence were found to be local (n=4; 13.8%), 
locoregional (n=3; 10.3%), regional (n=10; 34.5%), regional and distant (n=3, 10.3%) and 
distant metastases (n=9; 31.1%). 
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DISCUSSION 
Management of regional lymphatics among patients with head and neck cutaneous melanoma, 
especially indications for an elective lymph node dissection (ELND), has been questioned for 
decades. In the past, randomized controlled trials have been conducted to determine whether 
ELND in patients with melanoma decreases overall mortality compared with delayed 
lymphadenectomy at the time of clinical recurrence and no survival advantage has been 
observed2, 7, 34, 40. However, Lens et al.22 reported through performance of a meta-analysis 
(1533 participants) that these trials are of questionable validity since they contain significant 
methodological bias. Furthermore, previous studies involving melanomas from all anatomic 
sites showed a statistically significant improvement in survival in patient with intermediate 
thickness melanomas (range, 1-4 mm), which suggests that some subgroups of patients may 
benefit from ELND3, 25, 31. Finally, despite the fact that sentinel lymph node biopsy (SLNB) 
has been adopted into clinical practice as reliable staging modality, there are lots of arguments 
against it, such as increased incidence of nodal (regional and in-transit) recurrence in sentinel 
lymph nodes (SLN) negative patients, possibility of false-negative results, difficult 
identification of SLN if they are located close to primary site, SLN found in multiple node 
fields in contrast to melanomas located on extremities which usually drain to only 1 field, 
SLN in parotid region which are often very small, may be difficult to find, and their removal 
may put the facial nerve at risk8, 10, 12, 15, 16, 29, 36, 37. However, some authors reported that 
intraparotid SLN biopsy is a reliable, accurate, and safe procedure for staging cutaneous head 
and neck melanoma23. The finding that 1 in 4 patients had aberrant metastatic spread, which 
was not predicted clinically, is perhaps an indication that some patients may benefit from 
SLNB and lymphoscintigraphy. In this retrospective study, positron emission tomography 
(PET) was not used. Although PET’s inability to identify microscopic disease suggest that is 
of limited use in evaluating patients with stage I-II disease, PET can be helpful in managing 
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patients with stage III melanoma in whom further surgery is contemplated38. Furthermore, 
Iagaru et al.18 showed that PET has a sensitivity of 89% and a specificity of 88% for 
melanoma detection during restaging, and therefore should be an integral part in evaluation of 
patients with high-risk melanoma, prior to selection of the optimal treatment modality. 
 
On the basis of controlled trials and our clinical experience we believe that ELND should not 
be forgotten treatment modality and that some subgroups of patients may benefit from this 
procedure. 
 
It is generally agreed that preoperative clinical prediction of potential nodal metastatic sites 
based on anatomic location of the primary melanoma is difficult because of highly variable 
lymphatic pathways in the head and neck39, 41. In the present study, we have aimed to evaluate 
patterns of metastatic spread from primary melanoma site and to determine appropriate extent 
of surgery based on histological evaluation of neck dissection specimens. 
 
This study included patients with positive lymph node pathology detected in the neck, the 
parotid gland, combined parotid and neck involvement, and metastatic disease outside the 
parotid region and five main neck levels of lymph nodes. Tumour thickness was the most 
important factor in determining whether or not to perform an elective neck dissection (END). 
All patients with histological confirmed cutaneous melanoma thicker than 1mm or thicker 
than 0.7mm with a Clark level of 4 were considered candidates for END. No strict criteria 
were used to select the extent of parotid gland surgery; however patients with thick 
melanomas (>4mm) were more likely to undergo total parotidectomy, no matter if the 
procedure was performed on an elective or therapeutic basis. The procedure was done in 
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64.7% (22 out of 34) of those with thick melanomas versus 35.3% (12 out of 34) of those with 
intermediate thickness melanomas. 
 
Based on the incidence of involvement of parotid lymphatics, anatomic distribution of nodal 
metastases from levels I through V, and pathological involvement of lymph nodes outside of 
the five main lymph nodes levels of the neck, the following observations were made. Patients 
with melanomas of the face, forehead, coronal scalp, periauricular area, and upper neck were 
at high risk for the involvement of parotid lymphatics, whereas patients with posterior scalp 
and posterior neck melanomas did not have parotid metastases. These results suggest that 
parotidectomy should be considered for all head and neck subsites except for posterior 
primaries and lower neck melanomas. Based on the data from other series, some authors also 
recommend the use of parotidectomy as part of regional lymphadenectomy for patients with 
anterior primaries4, 30, 33. Finally, other studies reported significant and adverse influence of 
parotid involvement on survival5, 6, 27. Patients with both parotid and neck involvement 
demonstrated poorer prognosis than patients with neck involvement alone. It is important to 
be aware that parotid lymphatics are often affected with metastatic spread from upper neck 
primaries suggesting parotidectomy in conjunction with selective neck dissection. We believe 
that elective superficial parotidectomy is indicated because the parotid gland was 
histologically positive for metastatic melanoma in 16.1% of patients with clinically negative 
physical examinations. This incidence of subclinical disease is much higher than reported in 
the series by O’Brien et al. (2.4%)28. 
 
On the other side, patients with posterior scalp and posterior neck primaries had no 
involvement of the submandibular and submental triangles, or the parotid gland, so it may be 
justified to perform just a regional lymphadenectomy, excluding dissection of level 1 and any 
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parotidectomy. Also, patients with upper neck melanomas had no metastatic disease at levels 
4 and 5 and therefore it is recommended to exclude lower jugular lymph nodes and posterior 
triangle when considering surgical options and to rather perform a supraomohyoid dissection. 
Shah et al.33 identified similar patterns of metastatic spread from primary melanoma sites. 
According to results of this study, 5 of 45 patients had drainage in sites outside the parotid 
gland and five main levels of the neck. These patients demonstrated postauricular, nuchal and 
paratracheal lymph node involvement. Metastatic disease in postauricular and nuchal 
lymphatics was associated with posterior scalp and neck primaries. These lymph nodes are 
not typically dissected in standard neck dissections and spreading to these lymph node groups 
may be suspected. Previous studies also reported lymphatic drainage to these “discordant” 
sites from posterior primaries stressing that posterior neck dissection is mandatory and 
effective procedure to adequately resect the primary lymphatics which provides control of 
regional metastatic disease11, 14. On the other hand, O’Brien et al.30 reported metastatic spread 
to postauricular lymph nodes (1 of 18 patients with posterior scalp primaries and 2 of 26 
patients with coronal scalp melanomas) but no nuchal or occipital lymph node involvement 
was seen. Larson et al.20 stressed that among the sites of origin in the head and neck, 
melanoma of the scalp and neck carries the highest mortality, with 10-year survival being 
only 60%. Our recommended operations based on anatomic distribution of regional 
metastases are summarized in Figure 6. 
 
Also, results of this study show no statistically significant difference in pathologically 
involved levels between elective lymphadenectomies and therapeutic procedures and a similar 
distribution of nodal metastases no matter whether neck dissection has been performed based 
on an elective or therapeutic basis. The incidence of occult lymphatic disease among patients 
undergoing END was 17.8% (13 of 73 patients), which is consistent with the findings of prior 
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reports13, 35. Parotid lymph nodes were pathologically involved in 27.3% (21 of 77). Eight of 
45 patients (17.8%) had involvement of the parotid region only, so cervical lymph nodes are 
not necessarily the initial site of regional metastases and management of lymph nodes at this 
site represents a major issue among patients with melanomas originating in head and neck 
region. Authors from Memorial Sloan-Kettering Cancer Center described different results 
recommending complete radical neck dissection in therapeutic conditions and more limited 
surgery in elective procedures33. 
According to results of this study, patients with recurrence were predominant males (18 vs. 
11), had greater average melanoma thickness, higher percentage of 3 or more pathologically 
involved lymph nodes, higher incidence of extracapsular extension and higher percentage of 
parotid region drainage. However, none of the covariates tested (for recurrence rates) here 
were found to be statistically significant. Also, all this variables were compared using survival 
curves and only male gender differed significantly with respect to survival. On the other hand, 
some authors identified male gender, primary tumour thickness, type of neck dissection 
(elective vs. therapeutic), ECE, and number and size of regional metastases, as statistically 
significant independent negative prognostic factors21, 26. 
 
In conclusion, cutaneous melanomas of the head and neck metastasized to clinically predict 
nodal groups in 73.3% of patients in this series. This leaves a significant 26.7% of nodal 
metastases outside of the arbitrarily defined regions and therefore we believe it would be 
justifiable to perform more extensive dissection in primaries that have drainage to nodal 
basins outside of those predicted by the primary site. A similar distribution of nodal 
metastases was found, no matter if the neck dissection was performed on an elective or 
therapeutic basis. However, therapeutic dissections revealed aberrant regional metastases 
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83.3% of the time (10 out of 12), which supports the use of more extensive treatment than 
clinically indicated in settings of a clinically positive neck. 
 
Also, patients with clinical involvement of the parotid gland were at high risk of occult neck 
disease (40%) and therefore treatment of a clinically negative neck should be considered in 
presence of a clinically positive parotid gland to reduce the possibility of failure to detect 
cervical node involvement and to determine the extent of metastatic spread. 
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CAPTIONS TO ILLUSTRATIONS 
FIGURE (1) Survival curves comparing patients with an ulcerated and patients with a 
nonulcerated melanoma. Solid line = nonulcerated melanoma (n=68), dashed line = ulcerated 
melanoma (n= 28). Log-rank test, P=0.048. 
 
FIGURE (2) Kaplan-Meier curves showing overall survival of patients of different ages with 
head and neck cutaneous melanoma. Solid line = ages 21-40, dashed line = ages 41-60, and 
dotted line = ages 61 and above. Log-rank test, P=0.624. 
 
FIGURE (3) Kaplan-Meier curves showing cumulative melanoma-specific survival for 106 
patients and survival of patients separated by gender. Solid line=men (n=56), dashed 
line=women (n=50). Log-rank test, P=0.042. 
 
FIGURE (4) Kaplan-Meier survival curves of patients compared to nodal status. Solid line = 
negative neck (n=51), dashed line = positive neck (n=21), dotted line = positive parotid gland 
(n=8), dot-dashed line = positive both parotid and neck (n=12). Log-rank test, P<0.01. 
 
FIGURE (5) Distribution of the primary melanomas with pN+ among defined regions of the 
skin of the head and neck. 
 
FIGURE (6) Recommended operations based on anatomic distribution of regional metastases.  
 
 
Table 1 
 
Neck Dissection Elective ND Curative 
ND 
TOTAL 
ERND 6 10 16 
RND 14 12 26 
MRND  
 1. SAN 
 2. SAN + IJV 
 3. SAN + IJV  +      
SCM 
12 
9 
2 
1 
7 
5 
1 
1 
19 
 
SND 40 1 41 
MRNDBL 0 1 1 
MRND + RNDCL 1 1 2 
RND + SNDCL 1-3 0 1 1 
TOTAL 73 33 106 
 
 
Abbreviations: 
ERND = Extended Radical Neck Dissection 
RND = Radical Neck Dissection 
MRND = Modified Radical Neck Dissection 
SAN = Spinal Accessory Nerve 
IJV = Internal Jugular Vein 
SCM = Sternocleidomastoid Muscle 
SND = Selective Neck Dissection 
MRNDBL = Bilateral Modified Radical Neck Dissection 
RNDCL = Contralateral Radical Neck Dissection 
SNDCL = Contralateral Selective Neck Dissection 
 
Table 2 
Sex 
Male 
Female 
No. (%) 
28 (62.2) 
17 (37.8) 
Age 
Median 
Range 
y 
49 
21-75 
Primary melanoma site 
Face & forhead 
Coronal scalp & periauricular 
area 
Posterior scalp,upper & lower 
posterior neck 
Upper neck 
Lower anterior neck 
No (%) 
16 
16 
 
6 
6 
1 
Tumor thickness 
Mean 
Range 
mm 
4.2 
1-10 
Nodal metastases 
Average 
Range 
No 
3.98 
1-17 
Contralateral metastases after 
treatment 
No (%) 
6 (13.3) 
